Jessica Walters

Biogen's zuranolone gains positive opinion for treating postpartum depression, promising rapid symptom relief and potential EU approval by 2025.

Acumen Pharmaceuticals reveals a breakthrough blood assay that enhances Alzheimer’s trial efficiency and highlights sabirnetug's selectivity for toxic amyloid beta oligomers.

Explore the latest findings on neurotransmitter levels and innovative treatments for major depressive disorder, including TMS and cognitive impacts.

Stay informed on PTSD treatment insights, including complex PTSD recognition, diagnostic nuances, and the link between migraines and trauma.

Women with schizophrenia face increased breast cancer risks linked to long-term prolactin-raising antipsychotic use, highlighting the need for regular screenings and tailored treatment strategies.

A groundbreaking study reveals that reduced cortical thickness in the parahippocampus may indicate major depressive disorder and neuroticism traits.

Discover innovative strategies for early diagnosis and treatment of bipolar disorder, addressing challenges and exploring promising new therapies.

Discover groundbreaking schizophrenia treatment with xanomeline-trospium, targeting cholinergic pathways for improved symptoms and fewer side effects.

A groundbreaking study links antibiotic exposure to increased depression risk in adolescents, highlighting urinary analysis as a potential screening tool.

Researchers uncover a novel biomarker for major depressive disorder, linking regional homogeneity in fMRI to decreased cerebral blood flow and symptom severity.